ING5‐mediated antineuroblastoma effects of suberoylanilide hydroxamic acid
Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical outcomes and prognosis, discovering new promising drugs and targeted medicine is essential. We found that applying Suberoylanilide hydroxamic acid (SAH...
Saved in:
Published in | Cancer medicine (Malden, MA) Vol. 7; no. 9; pp. 4554 - 4569 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
John Wiley & Sons, Inc
01.09.2018
John Wiley and Sons Inc Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical outcomes and prognosis, discovering new promising drugs and targeted medicine is essential. We found that applying Suberoylanilide hydroxamic acid (SAHA; Vorinostat, a histone deacetylase inhibitor) and MG132 (a proteasome inhibitor) to SH‐SY5Y cells synergistically suppressed proliferation, glucose metabolism, migration, and invasion and induced apoptosis and cell cycle arrest. These effects occurred both concentration and time dependently and were associated with the effects observed with inhibitor of growth 5 (ING5) overexpression. SAHA and MG132 treatment increased the expression levels of ING5, PTEN, p53, Caspase‐3, Bax, p21, and p27 but decreased the expression levels of 14‐3‐3, MMP‐2, MMP‐9, ADFP, Nanog, c‐myc, CyclinD1, CyclinB1, and Cdc25c concentration dependently, similar to ING5. SAHA may downregulate miR‐543 and miR‐196‐b expression to enhance the translation of ING5 protein, which promotes acetylation of histones H3 and H4. All three proteins (ING5 and acetylated histones H3 and H4) were recruited to the promoters of c‐myc, Nanog, CyclinD1, p21, and p27 for complex formation, thereby regulating the mRNA expression of downstream genes. ING5 overexpression and SAHA and/or MG132 administration inhibited tumor growth in SH‐SY5Y cells by suppressing proliferation and inducing apoptosis. The expression of acetylated histones H3 and ING5 may be closely linked to the tumor size of neuroblastomas. In summary, SAHA and/or MG132 can synergistically suppress the malignant phenotypes of neuroblastoma cells through the miRNA‐ING5‐histone acetylation axis and via proteasomal degradation, respectively. Therefore, the two drugs may serve as potential treatments for neuroblastoma.
The treatment with SAHA (a histone deacetylase inhibitor) and MG132 (a proteasome inhibitor) synergistically suppressed proliferation, glucose metabolism, migration, and invasion, and induced apoptosis and cell cycle arrest of neuroblastoma cells in both concentration‐ and time‐dependent manners. SAHA and MG132 treatment upregulates the expression of ING5, which has the same effects as SAHA. SAHA may downregulate miR‐543 and miR‐196‐b expression to enhance the translation of ING5 protein. SAHA and ING5 overexpression promote the acetylation of histones H3 and H4. ING5 and acetyl‐histones H3 and H4 were recruited to the promoters of Nanog, c‐myc, CyclinD1, p21, and p27 for complex formation, which thereby regulates the mRNA expression of the latter genes. ING5 overexpression, SAHA, and/or MG132 administration suppressed tumor growth in SY5Y cells by inhibiting proliferation and inducing apoptosis. Expression of acetyl‐histone H3 and ING5 may be closely linked to tumor size of neuroblastoma. |
---|---|
AbstractList | Abstract Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical outcomes and prognosis, discovering new promising drugs and targeted medicine is essential. We found that applying Suberoylanilide hydroxamic acid (SAHA; Vorinostat, a histone deacetylase inhibitor) and MG132 (a proteasome inhibitor) to SH‐SY5Y cells synergistically suppressed proliferation, glucose metabolism, migration, and invasion and induced apoptosis and cell cycle arrest. These effects occurred both concentration and time dependently and were associated with the effects observed with inhibitor of growth 5 (ING5) overexpression. SAHA and MG132 treatment increased the expression levels of ING5, PTEN, p53, Caspase‐3, Bax, p21, and p27 but decreased the expression levels of 14‐3‐3, MMP‐2, MMP‐9, ADFP, Nanog, c‐myc, CyclinD1, CyclinB1, and Cdc25c concentration dependently, similar to ING5. SAHA may downregulate miR‐543 and miR‐196‐b expression to enhance the translation of ING5 protein, which promotes acetylation of histones H3 and H4. All three proteins (ING5 and acetylated histones H3 and H4) were recruited to the promoters of c‐myc, Nanog, CyclinD1, p21, and p27 for complex formation, thereby regulating the mRNA expression of downstream genes. ING5 overexpression and SAHA and/or MG132 administration inhibited tumor growth in SH‐SY5Y cells by suppressing proliferation and inducing apoptosis. The expression of acetylated histones H3 and ING5 may be closely linked to the tumor size of neuroblastomas. In summary, SAHA and/or MG132 can synergistically suppress the malignant phenotypes of neuroblastoma cells through the miRNA‐ING5‐histone acetylation axis and via proteasomal degradation, respectively. Therefore, the two drugs may serve as potential treatments for neuroblastoma. Abstract Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical outcomes and prognosis, discovering new promising drugs and targeted medicine is essential. We found that applying Suberoylanilide hydroxamic acid (SAHA; Vorinostat, a histone deacetylase inhibitor) and MG132 (a proteasome inhibitor) to SH‐SY5Y cells synergistically suppressed proliferation, glucose metabolism, migration, and invasion and induced apoptosis and cell cycle arrest. These effects occurred both concentration and time dependently and were associated with the effects observed with inhibitor of growth 5 (ING5) overexpression. SAHA and MG132 treatment increased the expression levels of ING5, PTEN, p53, Caspase‐3, Bax, p21, and p27 but decreased the expression levels of 14‐3‐3, MMP‐2, MMP‐9, ADFP, Nanog, c‐myc, CyclinD1, CyclinB1, and Cdc25c concentration dependently, similar to ING5. SAHA may downregulate miR‐543 and miR‐196‐b expression to enhance the translation of ING5 protein, which promotes acetylation of histones H3 and H4. All three proteins (ING5 and acetylated histones H3 and H4) were recruited to the promoters of c‐myc, Nanog, CyclinD1, p21, and p27 for complex formation, thereby regulating the mRNA expression of downstream genes. ING5 overexpression and SAHA and/or MG132 administration inhibited tumor growth in SH‐SY5Y cells by suppressing proliferation and inducing apoptosis. The expression of acetylated histones H3 and ING5 may be closely linked to the tumor size of neuroblastomas. In summary, SAHA and/or MG132 can synergistically suppress the malignant phenotypes of neuroblastoma cells through the miRNA‐ING5‐histone acetylation axis and via proteasomal degradation, respectively. Therefore, the two drugs may serve as potential treatments for neuroblastoma. Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical outcomes and prognosis, discovering new promising drugs and targeted medicine is essential. We found that applying Suberoylanilide hydroxamic acid (SAHA; Vorinostat, a histone deacetylase inhibitor) and MG132 (a proteasome inhibitor) to SH‐SY5Y cells synergistically suppressed proliferation, glucose metabolism, migration, and invasion and induced apoptosis and cell cycle arrest. These effects occurred both concentration and time dependently and were associated with the effects observed with inhibitor of growth 5 (ING5) overexpression. SAHA and MG132 treatment increased the expression levels of ING5, PTEN, p53, Caspase‐3, Bax, p21, and p27 but decreased the expression levels of 14‐3‐3, MMP‐2, MMP‐9, ADFP, Nanog, c‐myc, CyclinD1, CyclinB1, and Cdc25c concentration dependently, similar to ING5. SAHA may downregulate miR‐543 and miR‐196‐b expression to enhance the translation of ING5 protein, which promotes acetylation of histones H3 and H4. All three proteins (ING5 and acetylated histones H3 and H4) were recruited to the promoters of c‐myc, Nanog, CyclinD1, p21, and p27 for complex formation, thereby regulating the mRNA expression of downstream genes. ING5 overexpression and SAHA and/or MG132 administration inhibited tumor growth in SH‐SY5Y cells by suppressing proliferation and inducing apoptosis. The expression of acetylated histones H3 and ING5 may be closely linked to the tumor size of neuroblastomas. In summary, SAHA and/or MG132 can synergistically suppress the malignant phenotypes of neuroblastoma cells through the miRNA‐ING5‐histone acetylation axis and via proteasomal degradation, respectively. Therefore, the two drugs may serve as potential treatments for neuroblastoma. The treatment with SAHA (a histone deacetylase inhibitor) and MG132 (a proteasome inhibitor) synergistically suppressed proliferation, glucose metabolism, migration, and invasion, and induced apoptosis and cell cycle arrest of neuroblastoma cells in both concentration‐ and time‐dependent manners. SAHA and MG132 treatment upregulates the expression of ING5, which has the same effects as SAHA. SAHA may downregulate miR‐543 and miR‐196‐b expression to enhance the translation of ING5 protein. SAHA and ING5 overexpression promote the acetylation of histones H3 and H4. ING5 and acetyl‐histones H3 and H4 were recruited to the promoters of Nanog, c‐myc, CyclinD1, p21, and p27 for complex formation, which thereby regulates the mRNA expression of the latter genes. ING5 overexpression, SAHA, and/or MG132 administration suppressed tumor growth in SY5Y cells by inhibiting proliferation and inducing apoptosis. Expression of acetyl‐histone H3 and ING5 may be closely linked to tumor size of neuroblastoma. Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical outcomes and prognosis, discovering new promising drugs and targeted medicine is essential. We found that applying Suberoylanilide hydroxamic acid (SAHA; Vorinostat, a histone deacetylase inhibitor) and MG132 (a proteasome inhibitor) to SH‐SY5Y cells synergistically suppressed proliferation, glucose metabolism, migration, and invasion and induced apoptosis and cell cycle arrest. These effects occurred both concentration and time dependently and were associated with the effects observed with inhibitor of growth 5 (ING5) overexpression. SAHA and MG132 treatment increased the expression levels of ING5, PTEN, p53, Caspase‐3, Bax, p21, and p27 but decreased the expression levels of 14‐3‐3, MMP‐2, MMP‐9, ADFP, Nanog, c‐myc, CyclinD1, CyclinB1, and Cdc25c concentration dependently, similar to ING5. SAHA may downregulate miR‐543 and miR‐196‐b expression to enhance the translation of ING5 protein, which promotes acetylation of histones H3 and H4. All three proteins (ING5 and acetylated histones H3 and H4) were recruited to the promoters of c‐myc, Nanog, CyclinD1, p21, and p27 for complex formation, thereby regulating the mRNA expression of downstream genes. ING5 overexpression and SAHA and/or MG132 administration inhibited tumor growth in SH‐SY5Y cells by suppressing proliferation and inducing apoptosis. The expression of acetylated histones H3 and ING5 may be closely linked to the tumor size of neuroblastomas. In summary, SAHA and/or MG132 can synergistically suppress the malignant phenotypes of neuroblastoma cells through the miRNA‐ING5‐histone acetylation axis and via proteasomal degradation, respectively. Therefore, the two drugs may serve as potential treatments for neuroblastoma. Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical outcomes and prognosis, discovering new promising drugs and targeted medicine is essential. We found that applying Suberoylanilide hydroxamic acid (SAHA; Vorinostat, a histone deacetylase inhibitor) and MG132 (a proteasome inhibitor) to SH-SY5Y cells synergistically suppressed proliferation, glucose metabolism, migration, and invasion and induced apoptosis and cell cycle arrest. These effects occurred both concentration and time dependently and were associated with the effects observed with inhibitor of growth 5 (ING5) overexpression. SAHA and MG132 treatment increased the expression levels of ING5, PTEN, p53, Caspase-3, Bax, p21, and p27 but decreased the expression levels of 14-3-3, MMP-2, MMP-9, ADFP, Nanog, c-myc, CyclinD1, CyclinB1, and Cdc25c concentration dependently, similar to ING5. SAHA may downregulate miR-543 and miR-196-b expression to enhance the translation of ING5 protein, which promotes acetylation of histones H3 and H4. All three proteins (ING5 and acetylated histones H3 and H4) were recruited to the promoters of c-myc, Nanog, CyclinD1, p21, and p27 for complex formation, thereby regulating the mRNA expression of downstream genes. ING5 overexpression and SAHA and/or MG132 administration inhibited tumor growth in SH-SY5Y cells by suppressing proliferation and inducing apoptosis. The expression of acetylated histones H3 and ING5 may be closely linked to the tumor size of neuroblastomas. In summary, SAHA and/or MG132 can synergistically suppress the malignant phenotypes of neuroblastoma cells through the miRNA-ING5-histone acetylation axis and via proteasomal degradation, respectively. Therefore, the two drugs may serve as potential treatments for neuroblastoma. |
Author | Zheng, Hua‐chuan Yang, Xiang‐hong Wu, Ji‐cheng Jiang, Hua‐mao |
AuthorAffiliation | 2 Department of Pathology Shengjing Hospital of China Medical University Shenyang China 1 Tumor Basic and Translational Laboratory The First Affiliated Hospital of Jinzhou Medical University Jinzhou China |
AuthorAffiliation_xml | – name: 1 Tumor Basic and Translational Laboratory The First Affiliated Hospital of Jinzhou Medical University Jinzhou China – name: 2 Department of Pathology Shengjing Hospital of China Medical University Shenyang China |
Author_xml | – sequence: 1 givenname: Ji‐cheng surname: Wu fullname: Wu, Ji‐cheng organization: The First Affiliated Hospital of Jinzhou Medical University – sequence: 2 givenname: Hua‐mao surname: Jiang fullname: Jiang, Hua‐mao organization: The First Affiliated Hospital of Jinzhou Medical University – sequence: 3 givenname: Xiang‐hong surname: Yang fullname: Yang, Xiang‐hong organization: Shengjing Hospital of China Medical University – sequence: 4 givenname: Hua‐chuan orcidid: 0000-0001-9655-6940 surname: Zheng fullname: Zheng, Hua‐chuan email: zheng_huachuan@hotmail.com organization: The First Affiliated Hospital of Jinzhou Medical University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30091530$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kc9uEzEQhy3UipbQAy-AVuLEIa3_rjcXpCqCEim0FzhbY3vcOtpdF-8ukBuPwDPyJDhNqdpDffHI_vSNPb9X5KBPPRLyhtFTRik_c9DJU1YL-YIccyrVXJf64FF9RE6GYUPL0pTXmr0kR4LSBVOCHpP16vJC_f39p0MfYURfQT_GHqecbAvDmDqoMAR041ClUA2TxZy2LfSxjR6rm63P6Rd00VXgon9NDgO0A57c7zPy7dPHr8vP8_XVxWp5vp47pZWcW91w5VzwXlGhteBC1FJ47xdNo70WKALwQmrFeM0tpQ02guEicM4BPRMzstp7fYKNuc2xg7w1CaK5O0j52kAeo2vReJDSI4AOykou9cIq21gIdW0d9aIurg971-1kyxAc9mOG9on06U0fb8x1-mFqJiVTugje3Qty-j7hMJpNmnJf_m84o41uJCujnpH3e8rlNAwZw0MHRs0uR7PL0exyLOzbx096IP-nVoCzPfAztrh93mSW51_knfIfhKmp0w |
CitedBy_id | crossref_primary_10_3389_fonc_2021_617362 crossref_primary_10_1002_med_21750 crossref_primary_10_3390_ijms23105801 crossref_primary_10_3389_fonc_2022_918954 crossref_primary_10_1093_hmg_ddab370 crossref_primary_10_1177_09603271221150247 crossref_primary_10_1186_s11658_019_0189_2 crossref_primary_10_3389_fcell_2022_1012179 crossref_primary_10_1016_j_critrevonc_2019_03_013 crossref_primary_10_3389_fonc_2020_613679 |
Cites_doi | 10.1007/s11060-014-1575-2 10.1016/j.biocel.2008.05.026 10.18632/oncotarget.3842 10.18632/oncotarget.5642 10.1007/s00432-010-0815-x 10.1097/IGC.0000000000000703 10.1007/s13402-015-0233-9 10.1038/cdd.2016.117 10.18632/oncotarget.10519 10.1097/MPA.0b013e3182962acb 10.1371/journal.pone.0033860 10.1016/j.humpath.2010.05.024 10.1615/CritRevOncog.2015014033 10.18632/oncotarget.10643 10.1186/1868-7083-3-4 10.3892/or.2013.2481 10.1016/j.molcel.2005.12.007 10.1016/j.canlet.2014.10.034 10.1016/j.canlet.2015.11.017 10.1021/pr500497e 10.2217/fon.12.173 10.1186/s12935-014-0112-x 10.1002/jcp.24863 10.3892/ijo.2015.3240 10.1111/j.1582-4934.2008.00482.x 10.1038/43710 10.1016/j.ejca.2014.09.012 10.1089/scd.2011.0695 10.1016/j.oraloncology.2016.02.015 10.1002/ijc.28810 10.1016/j.molonc.2012.09.004 10.3892/ijo.2014.2337 10.1016/j.molonc.2012.09.003 10.1186/s13048-016-0301-4 10.18632/oncotarget.13680 10.1172/JCI69738 10.4161/cc.6.12.4409 10.18632/oncotarget.3735 10.1007/s12253-012-9499-7 10.1182/blood-2007-06-098061 10.1016/j.chemphyslip.2014.04.001 10.1038/sj.onc.1210204 10.1111/dote.12127 10.1074/jbc.M603724200 10.18632/oncotarget.3555 10.1038/srep06226 10.1038/bjc.2014.547 10.1186/1471-2202-12-50 10.1016/j.humpath.2009.12.018 10.1007/s13277-015-3497-9 |
ContentType | Journal Article |
Copyright | 2018 The Authors. published by John Wiley & Sons Ltd. 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2018 The Authors. published by John Wiley & Sons Ltd. – notice: 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. – notice: 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M7P PIMPY PQEST PQQKQ PQUKI PRINS 5PM DOA |
DOI | 10.1002/cam4.1634 |
DatabaseName | Wiley Open Access Wiley-Blackwell Backfiles (Open access) Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection AUTh Library subscriptions: ProQuest Central ProQuest Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) Biological Science Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | CrossRef MEDLINE Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | WU et al |
EISSN | 2045-7634 |
EndPage | 4569 |
ExternalDocumentID | oai_doaj_org_article_da44deaa7f5b42479b5b8baf66bc0d36 10_1002_cam4_1634 30091530 CAM41634 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | United States--US China |
GeographicLocations_xml | – name: China – name: United States--US |
GrantInformation_xml | – fundername: Shenyang Science and Technology Grand funderid: 18‐013‐0‐59 – fundername: National Natural Scientific Foundation of China funderid: 81472544; 81672700 – fundername: National Natural Scientific Foundation of China grantid: 81472544; 81672700 – fundername: Shenyang Science and Technology Grand grantid: 18‐013‐0‐59 |
GroupedDBID | 0R~ 1OC 24P 31~ 53G 5VS 7X7 8-0 8-1 8FE 8FH 8FI 8FJ AAHHS AAZKR ABDBF ABUWG ACCFJ ACXQS ADBBV ADKYN ADRAZ ADZMN ADZOD AEEZP AENEX AEQDE AFKRA AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU D-8 D-9 DIK EBS EJD FYUFA GODZA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE HZ~ IAO IHR KQ8 LK8 M48 M7P M~E O9- OK1 OVD PIMPY PQQKQ PROAC RPM TEORI TUS UKHRP WIN CGR CUY CVF ECM EIF ITC NPM AAYXX CITATION 3V. 7XB 8FK AZQEC DWQXO GNUQQ K9. PQEST PQUKI PRINS 5PM |
ID | FETCH-LOGICAL-c5754-b7825ccfdd503773233643ddd9887d73e3fa2575751262b008e831e9f222aed13 |
IEDL.DBID | RPM |
ISSN | 2045-7634 |
IngestDate | Tue Oct 22 15:16:46 EDT 2024 Tue Sep 17 20:57:08 EDT 2024 Thu Oct 10 19:20:45 EDT 2024 Thu Sep 26 15:30:45 EDT 2024 Sat Sep 28 08:26:10 EDT 2024 Sat Aug 24 00:58:33 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Keywords | neuroblastoma ING5 miRNA histone acetylation suberoylanilide hydroxamic acid |
Language | English |
License | Attribution 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5754-b7825ccfdd503773233643ddd9887d73e3fa2575751262b008e831e9f222aed13 |
ORCID | 0000-0001-9655-6940 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144157/ |
PMID | 30091530 |
PQID | 2108784115 |
PQPubID | 2032540 |
PageCount | 16 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_da44deaa7f5b42479b5b8baf66bc0d36 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6144157 proquest_journals_2108784115 crossref_primary_10_1002_cam4_1634 pubmed_primary_30091530 wiley_primary_10_1002_cam4_1634_CAM41634 |
PublicationCentury | 2000 |
PublicationDate | September 2018 |
PublicationDateYYYYMMDD | 2018-09-01 |
PublicationDate_xml | – month: 09 year: 2018 text: September 2018 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Bognor Regis – name: Hoboken |
PublicationTitle | Cancer medicine (Malden, MA) |
PublicationTitleAlternate | Cancer Med |
PublicationYear | 2018 |
Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
References | 2017; 8 2015; 36 2009; 41 2015; 6 2015; 38 2017; 24 2013; 42 2014; 27 2012; 18 2011; 12 2016; 280 2011; 3 1999; 401 2015; 8 2014; 44 2016; 56 2013; 9 2014; 135 2016; 7 2009; 13 2014; 4 2006; 21 2015; 356 2015; 20 2010; 136 2015; 112 2017; 10 2015; 230 2008; 28 2006; 26 2013; 30 2011; 42 2014; 14 2007; 6 2014; 13 2014; 181 2006; 281 2012; 6 2008; 111 2012; 7 2014; 50 2016; 48 2014; 120 2016; 26 2012; 21 2007; 26 2014; 124 e_1_2_7_5_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_17_1 e_1_2_7_15_1 e_1_2_7_41_1 e_1_2_7_13_1 e_1_2_7_11_1 e_1_2_7_45_1 e_1_2_7_47_1 e_1_2_7_26_1 e_1_2_7_49_1 e_1_2_7_28_1 Lu H (e_1_2_7_27_1) 2016; 7 e_1_2_7_50_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_52_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_54_1 e_1_2_7_21_1 e_1_2_7_35_1 e_1_2_7_37_1 e_1_2_7_39_1 e_1_2_7_6_1 e_1_2_7_4_1 Zheng H (e_1_2_7_40_1) 2006; 26 e_1_2_7_8_1 e_1_2_7_18_1 e_1_2_7_16_1 Yamamoto S (e_1_2_7_29_1) 2008; 28 e_1_2_7_2_1 e_1_2_7_14_1 e_1_2_7_42_1 e_1_2_7_12_1 e_1_2_7_44_1 e_1_2_7_10_1 e_1_2_7_46_1 e_1_2_7_48_1 e_1_2_7_51_1 e_1_2_7_30_1 e_1_2_7_53_1 Zhao QY (e_1_2_7_43_1) 2015; 8 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_38_1 |
References_xml | – volume: 27 start-page: 693 year: 2014 end-page: 702 article-title: Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo publication-title: Dis Esophagus – volume: 26 start-page: 3579 year: 2006 end-page: 3583 article-title: Expressions of MMP‐2, MMP‐9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma publication-title: Anticancer Res – volume: 281 start-page: 24161 year: 2006 end-page: 24170 article-title: DNA damage‐induced down‐regulation of human Cdc25C and Cdc2 is mediated by cooperation between p53 and maintenance DNA (cytosine‐5) methyltransferase 1 publication-title: J Biol Chem – volume: 50 start-page: 3243 year: 2014 end-page: 3261 article-title: Synergism of arsenic trioxide and MG132 in Raji cells attained by targeting BNIP3, autophagy, and mitochondria with low doses of valproic acid and vincristine publication-title: Eur J Cancer – volume: 42 start-page: 25 year: 2011 end-page: 35 article-title: The altered expression of ING5 protein is involved in gastric carcinogenesis and subsequent progression publication-title: Hum Pathol – volume: 41 start-page: 736 year: 2009 end-page: 739 article-title: Zn (II)‐dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A publication-title: Int J Biochem Cell Biol – volume: 401 start-page: 188 year: 1999 end-page: 193 article-title: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors publication-title: Nature – volume: 6 start-page: 19552 year: 2015 end-page: 19579 article-title: ING5 suppresses proliferation, apoptosis, migration and invasion, and induces autophagy and differentiation of gastric cancer cells: a good marker for carcinogenesis and subsequent progression publication-title: Oncotarget – volume: 56 start-page: 32 year: 2016 end-page: 39 article-title: Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs publication-title: Oral Oncol – volume: 8 start-page: 3156 year: 2017 end-page: 3169 article-title: SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: an in vitro and vivo study publication-title: Oncotarget – volume: 21 start-page: 51 year: 2006 end-page: 64 article-title: ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation publication-title: Mol Cell – volume: 7 start-page: 54596 year: 2016 end-page: 54615 article-title: The down‐regulated ING5 expression in lung cancer: a potential target of gene therapy publication-title: Oncotarget – volume: 48 start-page: 409 year: 2016 end-page: 420 article-title: Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines publication-title: Int J Oncol – volume: 135 start-page: 1721 year: 2014 end-page: 1732 article-title: Simultaneous NF‐κB inhibition and E‐cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo publication-title: Int J Cancer – volume: 28 start-page: 1585 year: 2008 end-page: 1591 article-title: Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy‐ associated cell death in chondrosarcoma cell lines publication-title: Anticancer Res – volume: 6 start-page: 637 year: 2012 end-page: 656 article-title: HDAC inhibitor‐based therapies: can we interpret the code? publication-title: Mol Oncol – volume: 10 start-page: 1 year: 2017 article-title: MiR‐1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression publication-title: J Ovarian Res – volume: 124 start-page: 30 year: 2014 end-page: 39 article-title: New and emerging HDAC inhibitors for cancer treatment publication-title: J Clin Invest – volume: 36 start-page: 9347 year: 2015 end-page: 9356 article-title: Suberoylanilide hydroxamic acid enhances chemosensitivity to 5‐fluorouracil in hepatocellular carcinoma via inhibition of thymidylate synthase publication-title: Tumour Biol – volume: 356 start-page: 828 year: 2015 end-page: 836 article-title: SAHA triggered MET activation contributes to SAHA tolerance in solid cancer cells publication-title: Cancer Lett – volume: 13 start-page: 4211 year: 2014 end-page: 4219 article-title: SAHA regulates histone acetylation, Butyrylation, and protein expression in neuroblastoma publication-title: J Proteome Res – volume: 18 start-page: 713 year: 2012 end-page: 720 article-title: SAHA Inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of Cyclin D1 and survivin publication-title: Pathol Oncol Res – volume: 6 start-page: 10195 year: 2015 end-page: 10206 article-title: The miR‐193a‐3p‐regulated ING5 gene activates the DNA damage response pathway and inhibits multi‐chemoresistance in bladder cancer publication-title: Oncotarget – volume: 21 start-page: 2508 year: 2012 end-page: 2519 article-title: MicroRNA‐193 pro‐proliferation effects for bone mesenchymal stem cells after low‐level laser irradiation treatment through inhibitor of growth family, member 5 publication-title: Stem Cells Dev – volume: 3 start-page: 4 year: 2011 article-title: Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells publication-title: Clin Epigenetics – volume: 44 start-page: 1745 year: 2014 end-page: 1755 article-title: Suberoylanilide hydroxamic acid‐induced HeLa cell death is closely correlated with oxidative stress and thioredoxin 1 levels publication-title: Int J Oncol – volume: 7 start-page: e33860 year: 2012 article-title: Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenografts publication-title: PLoS ONE – volume: 13 start-page: 2115 year: 2009 end-page: 2121 article-title: Prognostic role of global DNA‐methylation and histone acetylation in pT1a clear cell renal carcinoma in partial nephrectomy specimens publication-title: J Cell Mol Med – volume: 20 start-page: 245 year: 2015 end-page: 270 article-title: Neuroblastoma publication-title: Crit Rev Oncog – volume: 6 start-page: 16239 year: 2015 end-page: 16252 article-title: ING5 inhibits cancer aggressiveness via preventing EMT and is a potential prognostic biomarker for lung cancer publication-title: Oncotarget – volume: 136 start-page: 1573 year: 2010 end-page: 1578 article-title: Decreased nuclear expression and increased cytoplasmic expression of ING5 may be linked to tumorigenesis and progression in human head and neck squamous cell carcinoma publication-title: J Cancer Res Clin Oncol – volume: 7 start-page: 56508 year: 2016 end-page: 56525 article-title: The in vitro and vivo anti‐tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells publication-title: Oncotarget – volume: 14 start-page: 112 year: 2014 article-title: Effects of suberoylanilide hydroxamic acid (SAHA) combined with paclitaxel (PTX) on paclitaxel‐resistant ovarian cancer cells and insights into the underlying mechanisms publication-title: Cancer Cell Int – volume: 9 start-page: 255 year: 2013 end-page: 269 article-title: Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials publication-title: Future Oncol – volume: 6 start-page: 1419 year: 2007 end-page: 1425 article-title: Two distinct controls of mitotic cdk1/cyclin B1 activity requisite for cell growth prior to cell division publication-title: Cell Cycle – volume: 42 start-page: 1169 year: 2013 end-page: 1181 article-title: Aberrant expression miR‐196a is associated with abnormal apoptosis, invasion, and proliferation of pancreatic cancer cells publication-title: Pancreas – volume: 38 start-page: 341 year: 2015 end-page: 352 article-title: MYCN concurrence with SAHA‐ induced cell death in human neuroblastoma cells publication-title: Cell Oncol (Dordr) – volume: 280 start-page: 304 year: 2016 end-page: 314 article-title: More than the genes, the tumor microenvironment in neuroblastoma publication-title: Cancer Lett – volume: 30 start-page: 560 year: 2013 end-page: 566 article-title: Pin1‐Nanog expression in human glioma is correlated with advanced tumor progression publication-title: Oncol Rep – volume: 120 start-page: 459 year: 2014 end-page: 472 article-title: Co‐administration of ABT‐737 and SAHA induces apoptosis, mediated by Noxa upregulation, Bax activation and mitochondrial dysfunction in PTEN‐intact malignant human glioma cell lines publication-title: J Neurooncol – volume: 6 start-page: 38093 year: 2015 end-page: 38106 article-title: Upregulated in Hepatitis B virus‐associated hepatocellular carcinoma cells, miR‐331‐3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5 publication-title: Oncotarget – volume: 8 start-page: 15498 year: 2015 end-page: 15505 article-title: ING5 inhibits epithelial‐mesenchymal transition in breast cancer by suppressing PI3K/Akt pathway publication-title: Int J Clin Exp Med – volume: 24 start-page: 8 year: 2017 end-page: 14 article-title: p53 on the crossroad between regeneration and cancer publication-title: Cell Death Differ – volume: 4 start-page: 6226 year: 2014 article-title: Histone deacetylases inhibition by SAHA/Vorinostat normalizes the glioma micro‐ environment via xCT equilibration publication-title: Sci Rep – volume: 26 start-page: 1351 year: 2007 end-page: 1356 article-title: Discovery and development of SAHA as an anticancer agent publication-title: Oncogene – volume: 181 start-page: 62 year: 2014 end-page: 75 article-title: Mitochondrial alterations in apoptosis publication-title: Chem Phys Lipids – volume: 42 start-page: 424 year: 2011 end-page: 433 article-title: The nuclear to cytoplasmic shift of ING5 protein during colorectal carcinogenesis with their distinct links to pathologic behaviors of carcinomas publication-title: Hum Pathol – volume: 230 start-page: 1276 year: 2015 end-page: 1289 article-title: The synergistic effect of SAHA and parthenolide in MDA‐MB231 breast cancer cells publication-title: J Cell Physiol – volume: 26 start-page: 839 year: 2016 end-page: 844 article-title: Proteasome inhibitor MG132 enhances sensitivity to cisplatin on ovarian carcinoma cells in vitro and in vivo publication-title: Int J Gynecol Cancer – volume: 12 start-page: 50 year: 2011 article-title: Histone deacetylase inhibitors SAHA and sodium butyrate block G1‐to‐S cell cycle progression in neurosphere formation by adult subventricular cells publication-title: BMC Neurosci – volume: 111 start-page: 1060 year: 2008 end-page: 1166 article-title: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes publication-title: Blood – volume: 6 start-page: 657 year: 2012 end-page: 682 article-title: Trials with ‘epigenetic’ drugs: an update publication-title: Mol Oncol – volume: 112 start-page: 112 year: 2015 end-page: 121 article-title: Histone deacetylase inhibitor SAHA epigenetically regulates miR‐17‐92 cluster and MCM7 to upregulate MICA expression in hepatoma publication-title: Br J Cancer – ident: e_1_2_7_31_1 doi: 10.1007/s11060-014-1575-2 – ident: e_1_2_7_7_1 doi: 10.1016/j.biocel.2008.05.026 – ident: e_1_2_7_44_1 doi: 10.18632/oncotarget.3842 – ident: e_1_2_7_47_1 doi: 10.18632/oncotarget.5642 – ident: e_1_2_7_54_1 doi: 10.1007/s00432-010-0815-x – ident: e_1_2_7_33_1 doi: 10.1097/IGC.0000000000000703 – ident: e_1_2_7_16_1 doi: 10.1007/s13402-015-0233-9 – ident: e_1_2_7_37_1 doi: 10.1038/cdd.2016.117 – ident: e_1_2_7_42_1 doi: 10.18632/oncotarget.10519 – ident: e_1_2_7_49_1 doi: 10.1097/MPA.0b013e3182962acb – ident: e_1_2_7_32_1 doi: 10.1371/journal.pone.0033860 – ident: e_1_2_7_53_1 doi: 10.1016/j.humpath.2010.05.024 – ident: e_1_2_7_3_1 doi: 10.1615/CritRevOncog.2015014033 – volume: 7 start-page: 56508 year: 2016 ident: e_1_2_7_27_1 article-title: The in vitro and vivo anti‐tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells publication-title: Oncotarget doi: 10.18632/oncotarget.10643 contributor: fullname: Lu H – volume: 28 start-page: 1585 year: 2008 ident: e_1_2_7_29_1 article-title: Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy‐ associated cell death in chondrosarcoma cell lines publication-title: Anticancer Res contributor: fullname: Yamamoto S – ident: e_1_2_7_4_1 doi: 10.1186/1868-7083-3-4 – ident: e_1_2_7_41_1 doi: 10.3892/or.2013.2481 – ident: e_1_2_7_9_1 doi: 10.1016/j.molcel.2005.12.007 – ident: e_1_2_7_12_1 doi: 10.1016/j.canlet.2014.10.034 – ident: e_1_2_7_2_1 doi: 10.1016/j.canlet.2015.11.017 – ident: e_1_2_7_17_1 doi: 10.1021/pr500497e – volume: 26 start-page: 3579 year: 2006 ident: e_1_2_7_40_1 article-title: Expressions of MMP‐2, MMP‐9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma publication-title: Anticancer Res contributor: fullname: Zheng H – ident: e_1_2_7_22_1 doi: 10.2217/fon.12.173 – ident: e_1_2_7_11_1 doi: 10.1186/s12935-014-0112-x – ident: e_1_2_7_26_1 doi: 10.1002/jcp.24863 – ident: e_1_2_7_23_1 doi: 10.3892/ijo.2015.3240 – ident: e_1_2_7_51_1 doi: 10.1111/j.1582-4934.2008.00482.x – ident: e_1_2_7_5_1 doi: 10.1038/43710 – ident: e_1_2_7_34_1 doi: 10.1016/j.ejca.2014.09.012 – ident: e_1_2_7_50_1 doi: 10.1089/scd.2011.0695 – ident: e_1_2_7_14_1 doi: 10.1016/j.oraloncology.2016.02.015 – ident: e_1_2_7_8_1 doi: 10.1002/ijc.28810 – ident: e_1_2_7_20_1 doi: 10.1016/j.molonc.2012.09.004 – ident: e_1_2_7_10_1 doi: 10.3892/ijo.2014.2337 – ident: e_1_2_7_21_1 doi: 10.1016/j.molonc.2012.09.003 – ident: e_1_2_7_46_1 doi: 10.1186/s13048-016-0301-4 – ident: e_1_2_7_18_1 doi: 10.18632/oncotarget.13680 – ident: e_1_2_7_19_1 doi: 10.1172/JCI69738 – ident: e_1_2_7_38_1 doi: 10.4161/cc.6.12.4409 – ident: e_1_2_7_45_1 doi: 10.18632/oncotarget.3735 – ident: e_1_2_7_28_1 doi: 10.1007/s12253-012-9499-7 – ident: e_1_2_7_30_1 doi: 10.1182/blood-2007-06-098061 – ident: e_1_2_7_39_1 doi: 10.1016/j.chemphyslip.2014.04.001 – ident: e_1_2_7_6_1 doi: 10.1038/sj.onc.1210204 – ident: e_1_2_7_24_1 doi: 10.1111/dote.12127 – volume: 8 start-page: 15498 year: 2015 ident: e_1_2_7_43_1 article-title: ING5 inhibits epithelial‐mesenchymal transition in breast cancer by suppressing PI3K/Akt pathway publication-title: Int J Clin Exp Med contributor: fullname: Zhao QY – ident: e_1_2_7_36_1 doi: 10.1074/jbc.M603724200 – ident: e_1_2_7_48_1 doi: 10.18632/oncotarget.3555 – ident: e_1_2_7_15_1 doi: 10.1038/srep06226 – ident: e_1_2_7_13_1 doi: 10.1038/bjc.2014.547 – ident: e_1_2_7_35_1 doi: 10.1186/1471-2202-12-50 – ident: e_1_2_7_52_1 doi: 10.1016/j.humpath.2009.12.018 – ident: e_1_2_7_25_1 doi: 10.1007/s13277-015-3497-9 |
SSID | ssj0000702671 |
Score | 2.208039 |
Snippet | Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical outcomes... Abstract Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical... Abstract Neuroblastoma is the most common extracranial solid neuroendocrine cancer and is one of the leading causes of death in children. To improve clinical... |
SourceID | doaj pubmedcentral proquest crossref pubmed wiley |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 4554 |
SubjectTerms | Acetylation Animals Antineoplastic Agents - pharmacology Apoptosis Apoptosis - drug effects Apoptosis - genetics BAX protein Biomarkers Cancer Biology Caspase Cell cycle Cell Cycle - drug effects Cell Line, Tumor Cell proliferation Chromatin Cyclin-dependent kinase inhibitor p21 Disease Models, Animal Energy Metabolism - drug effects Gene expression Gene Expression Regulation, Neoplastic - drug effects Glucose metabolism histone acetylation Histone deacetylase Histone Deacetylase Inhibitors - pharmacology Histones - metabolism Humans Hydroxamic acid Immunohistochemistry ING5 Leupeptins - pharmacology Mice MicroRNAs - genetics miRNA Models, Biological Myc protein Neuroblastoma Neuroblastoma - drug therapy Neuroblastoma - genetics Neuroblastoma - metabolism Neuroblasts Neuroendocrine tumors Original Research p53 Protein Phenotypes Proteasome inhibitors Proteasomes PTEN protein Signal Transduction suberoylanilide hydroxamic acid Transcription Factors - genetics Transcription Factors - metabolism Tumor Suppressor Proteins - genetics Tumor Suppressor Proteins - metabolism Vorinostat - pharmacology Xenograft Model Antitumor Assays |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwEB0hDhUXxDdplypCHLgE7NiOk-MWFShiORWJmzWOHbESZCtYpHLjJ_Q39pd07GTRrlrUC9fEUux5seeNZvwG4IChRKYszziR5UxyLzIaiZlCW6AQnvEyXE4eXRXn1_LiRt3MtfoKNWGdPHBnuGOHUjqPqBtlZS51ZZUtLTZFYWvmRCe2zaq5YCqewTp0VuIzKSGWH9d4L4-IfMgFBxR1-v9FLv-ukZznrtH5nK7Bas8a02E323VY8u0GfBj1efFNuPx2daZ-v_yK90CIQ6YYGkAE3Q1L7Hg6uce0L9xIJ036-BSqRJ7vsB3fjZ1Pb5_dw-RnaEyfYj12W3B9-vX7yXnW90nIaiJbMrPk5VVdN84pJrQWuRDEM5xzFZ0gTgsvGqSdGTIseZHTPit9KbivGuIG6B0X27DcTlq_CylFIxQ_NIXPbS1tlVtEVtVci8Jh5RwmsD8znvnRyWGYTvg4N8HCJlg4gS_BrK8DgoJ1fEC4mh5X8z9cExjMQDH9tno0hHQZEqVcJbDT4fP6FUFskY5vloBeQG5hGotv2vFtFNQuYlSpEziMGL-9MnMyHAUGKz--xxI_wQrRr7KrWBvA8vThye8RxZnaz_Fv_gMxjfwU priority: 102 providerName: Directory of Open Access Journals – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BVkJcqvIOLShCHLiEOn4lOaG2aimIXSFEpd6scezQldqk3d1K9MZP4DfySxgn3oUVj2tiKc6MZ_yNZ_wNwEuGEpmyeZYTWM5k7kVGIzFTaDUK4VlehsvJ44k-PpHvT9VpPHCbx7LKpU_sHbXr6nBGvkuhSRlyZLl6c3mVha5RIbsaW2jchg1OkQIbwcb-4eTjp9UpCy1orot8SSnE-G6NF_I1gRC5thH1fP1_A5l_1kr-jmH7TehoCzYjekz3BnXfg1u-vQ93xjE__gA-vJu8VT--fe_vgxCWTDE0ggj8G5ZQ8qK7wDQWcKRdk86vQ7XIzTm20_Op8-nZjZt1X0OD-hTrqXsIJ0eHnw-Os9gvIasJdMnM0m6v6rpxTjFRFIILQXjDOVeRJ3GF8KJBstCQaeGak72VvhS5rxrCCOhdLh7BqO1a_wRSikoojmi057aWtuIWkVV1XgjtsHIOE3ixFJ65HGgxzECAzE2QsAkSTmA_iHU1IDBZ9w-62RcTDcM4lNJ5xKJRVnJZVFbZ0mKjta2ZEzqBnaVSTDSvufm1GBJ4POhn9RVBqJHcOEugWNPc2jTW37TTs55YW_fRZZHAq17H__4zc7A3DkhWPv3_7LbhLgGscqhJ24HRYnbtnxGIWdjncaX-BL3281I priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ1Lb9QwEMdHpUiIC-JNoEUR4sAlJY5fyaFCbUUpiO2JlXqzxrFDV9omsN1K3Rsfgc_YT8LYSaquKDeuiaMkM378Rh7_B-BtjgJzaVnGCJYzwTzPqCVmEq1Czn3OynA4eXKsjqbiy4k82YCxxuZgwPNbQ7tQT2q6mO9c_lx9oAG_OwiIvq_xTOwQV4g7cLcQFKCHDL6B8uOErEOZJTbqCt18Ym01iqL9t5Hm3wmTN0E2rkSHD-HBgJDpXu_zR7Dh28dwbzJskj-Br5-PP8mrX7_joRACyhRDNYggwmEJlZfdGaZDFkfaNen5RUgZWc2xnc1nzqenK7foLkOV-hTrmXsK08OP3w6OsqFoQlYTeYnM0pIv67pxTuZca15wTtDhnKtoOnGae94gDdOw3VKoggZd6UvOfNUQKKB3jD-DzbZr_QtIKTShYKJRvrC1sFVhEfOqZporh5VzmMCb0XjmR6-NYXoV5MIEC5tg4QT2g1mvGwQ563ihW3w3w-gwDoVwHlE30opC6MpKW1pslLJ17rhKYGt0ihm7iKFgtQy7pkwm8Lz3z_VbOKEjzeV5AnrNc2ufsX6nnZ1GdW0VQ0ydwLvo43__mTnYmwScFS__xy--gvvEYmWfvrYFm8vFhd8m3lna17E3_wH6AgGI priority: 102 providerName: Scholars Portal – databaseName: Wiley Open Access dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwEB2VIiEuiG8CBUWIA5fQxF9JxKlUlILYigOVerPGsdOu1CZodyvRGz-B38gvYcbJBlaAxDVxlGTGz37jGT8DvMhRYa5dkRVEljNVBJlRS8w0OoNShryoeHPy7MgcHqsPJ_pkC16v98IM-hDTghsjI47XDHB0y91foqENXqhXxCbUNbjOijEsnC_Up2mBhfqyMDHgYsX1jHCk1spCudidnt6Yj6Js_9-45p8lk79T2TgXHdyGWyOJTPcGr9-BrdDdhRuzMU1-Dz6-P3qnf3z7HreFEKVMkc-DYBkOR2R51V9gOtZxpH2bLi-5aOTqHLv5-dyH9OzKL_qvfE59is3c34fjg7ef9w-z8diErCHupTJHk75umtZ7ncuylEJKoh3e-5oGFF_KIFskoHLCRRhBsKtCJYtQt0QVMPhCPoDtru_CI0gpOKFwojVBuEa5WjjEvG6KUhqPtfeYwPO18eyXQR3DDjrIwrKFLVs4gTds1qkBC1rHC_3i1I74sB6V8gGxbLVTQpW1065y2BrjmtxLk8DO2il2RNnSUrhacd600Ak8HPwzvUUSeaTRPE-g3PDcxmds3unmZ1Ff28Qgs0zgZfTxv__M7u_NmNCqx__f9AncJM5VDWVqO7C9WlyGp8RrVu5Z7L8_AYTK88E priority: 102 providerName: Wiley-Blackwell |
Title | ING5‐mediated antineuroblastoma effects of suberoylanilide hydroxamic acid |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcam4.1634 https://www.ncbi.nlm.nih.gov/pubmed/30091530 https://www.proquest.com/docview/2108784115 https://pubmed.ncbi.nlm.nih.gov/PMC6144157 https://doaj.org/article/da44deaa7f5b42479b5b8baf66bc0d36 |
Volume | 7 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB51i4S4IN4EyipCHLhkN47tODm2qz5AZLVCVNpb5FfaSLtJtd1K9MZP4DfySxg7SdUVcOHiQ2LJzjzsb-LPMwAfYslkzBWJCILliBFLI-wpIy5VKim1Mcnc5eRinp6ds89LvtwDPtyF8aR9repJs1pPmvrScyuv1no68MSmi2KW-ihATEcwQgO9F6L75Ve4okpkyCIUJ1Mt12yCuMPV4KGIKdDJ451tyGfr_xvE_JMpeR_B-i3o5Ak87rFjeNjN8Sns2eYZPCz60_Hn8OXT_JT_-vHT3wZBJBlKVwbCZd9QiJG37VqGPX0jbKvw-sZxRW5XsqlXtbHh5a3ZtN9defpQ6tq8gPOT42-zs6ivlhBphFwsUrjXc60rY3hMhaAJpYg2jDE5riNGUEsrif7pzlmSNEFvy2xGic0rRAjSGkJfwn7TNvY1hBiTYBRRpTZRmqk8UVLGuSaCpkbmxsgA3g_CK6-6pBhll_44KZ2wSyfsAI6cWO86uDzW_kG7uSh7bZZGMmaslKLiiiVM5IqrTMkqTZWODU0DOBiUUvbOdV1ilJq541LCA3jV6edulEG_AYgdze1MY_cNWplPq91bVQAfvY7__WXl7LBwOJa9-e9B3sIjRF5ZR1Y7gP3t5sa-Q3SzVWMYJWyBrViKMTw4Op4vvo79nwJsT5cE24JlY2_zvwGKNwEJ |
link.rule.ids | 230,315,730,783,787,867,888,2109,2228,11574,12068,21400,24330,27936,27937,31731,33756,43322,43817,46064,46488,50826,50935,53804,53806,74073,74630 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BKwEXVF4l0EKEOHAJTfxKcqraqmWB7gqhVurNGscOXalNyu5Wojd-Ar-xv6TjxLtlxeOaWIoz4xl_4xl_A_A2RYGpNFmSEVhOROZ4QiMxkWgUcu7SrPCXk4cjNTgWn07kSThwm4ayyrlP7By1bSt_Rr5FoUnhc2SZ3L74nviuUT67Glpo3IVVT1VFwdfq7v7oy9fFKQstaKbybE4plLKtCs_FewIhYmkj6vj6_wYy_6yV_B3DdpvQwRo8DOgx3unV_QjuuOYx3BuG_PgTOPw4-iCvf_7q7oMQlozRN4Lw_BuGUPKsPcc4FHDEbR1PL321yNUZNuOzsXXx6ZWdtD98g_oYq7F9CscH-0d7gyT0S0gqAl0iMbTby6qqrZUpz3POOCe8Ya0tyZPYnDteI1moz7QwxcjeClfwzJU1YQR0NuPPYKVpG_ccYopKKI6olWOmEqZkBjEtqyznymJpLUbwZi48fdHTYuieAJlpL2HtJRzBrhfrYoBnsu4etJNvOhiGtiiEdYh5LY1gIi-NNIXBWilTpZarCDbmStHBvKb6djFEsN7rZ_EVTqiR3HgaQb6kuaVpLL9pxqcdsbbqoss8gnedjv_9Z3pvZ-iRrHjx_9m9hvuDo-GhJu1_fgkPCGwVfX3aBqzMJpdukwDNzLwKq_YGcZf2TA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BVqq4IN5NKRAhDlzCxrFjJyfUli7lsasKUak3axw7dKU2aXe3Er3xE_iN_BLGiXdhxeOaWIozz2884xmAFykKTHPDEkZgORHM8YRWYpKjkci5S1nhLyePJ_LwWLw_yU9C_dM8lFUubWJnqG1b-TPyIYUmhc-RsXxYh7KIozej1xeXiZ8g5TOtYZzGTdhQQvJ0ABt7B5OjT6sTFxLuTCq2bC-UZsMKz8UrAiRizSl1vfv_Bjj_rJv8Hc92Dml0B24HJBnv9qy_Czdccw82xyFXfh8-vpu8zX98-97dDSFcGaMfCuF7cRhCzIv2HONQzBG3dTy_8pUj12fYTM-m1sWn13bWfvXD6mOspvYBHI8OPu8fJmF2QlIRABOJIc-fV1VtbZ5ypXjGOWEPa21JVsUq7niNpK0-65LJjHSvcAVnrqwJL6CzjD-EQdM2bgtiilAopqily0wlTJkZxLSsmOLSYmktRvB8STx90bfI0H0z5Ex7CmtP4Qj2PFlXC3xX6-5BO_uig5Joi0JYh6jq3IhMqNLkpjBYS2mq1HIZwc6SKTqo2lz_EowIHvX8WX2FE4Ikk55GoNY4t7aN9TfN9LRrsi27SFNF8LLj8b__TO_vjj2qFdv_390z2CSB1cT8D4_hFuGuoi9V24HBYnblnhC2WZinQWh_Asf8-no |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ING5%E2%80%90mediated+antineuroblastoma+effects+of+suberoylanilide+hydroxamic+acid&rft.jtitle=Cancer+medicine+%28Malden%2C+MA%29&rft.au=Ji%E2%80%90cheng+Wu&rft.au=Hua%E2%80%90mao+Jiang&rft.au=Xiang%E2%80%90hong+Yang&rft.au=Hua%E2%80%90chuan+Zheng&rft.date=2018-09-01&rft.pub=Wiley&rft.eissn=2045-7634&rft.volume=7&rft.issue=9&rft.spage=4554&rft.epage=4569&rft_id=info:doi/10.1002%2Fcam4.1634&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_da44deaa7f5b42479b5b8baf66bc0d36 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-7634&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-7634&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-7634&client=summon |